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Abstract
The microRNA-34 family (miR-34a, -34b and -34c) have been reported to be tumor sup-
pressor microRNAs (miRNAs) that are regulated by the TP53 and DNA hypermethylation.
However, the expression, regulation, and prognostic value of the miR-34 family have not
been systematically studied in colon cancer. To elucidate the roles of miR-34 family in colon
carcinogenesis, miR-34a/b/c were measured in tumors and adjacent noncancerous tissues
from 159 American and 113 Chinese colon cancer patients using quantitative RT-PCR, and
we examined associations between miR-34a/b/c expression with TNM staging, cancer-spe-
cific mortality, TP53 mutation status and Affymetrix microarray data. All miR-34 family mem-
bers were significantly increased in colon tumors, counter to the proposed tumor
suppressor role for these miRNAs. Increased miR-34b/c were observed in more advanced
tumors in two independent cohorts and increased expression of miR-34b/c was associated
with poor cancer-specific mortality. While the expression of miR-34 family was not associat-
ed with TP53 mutation status, TP53 transcriptional activity was associated with miR-34a/b/
c expression that is consistent with the proposed regulation of miR-34a/b/c by TP53. To ex-
amine where the miR-34 family is expressed, the expression of miR-34 family was com-
pared between epitheliums and stromal tissues using laser microdissection technique. The
expression of miR-34b/c was increased significantly in stromal tissues, especially in cancer
stroma, compared with epithelial tissue. In conclusion, increased miR-34b/c predominantly
expressed in stromal tissues is associated with poor prognosis in colon cancer. MiR-34 may
contribute to cancer-stromal interaction associated with colon cancer progression.
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Introduction
Colorectal cancer is the third most common cancer and the fourth leading cause of cancer-re-
lated death worldwide. Approximately 1.2 million new cases and about 600,000 deaths estimat-
ed occur annually [1]. Further studies to discover risk factors, biomarkers and therapeutic
targets for colorectal cancer may help reduce the burden of this cancer.
MicroRNAs (miRNAs) are non-coding, single-stranded RNAs that are 18–25 nucleotides
long. Since their discovery, miRNAs have been found to down-regulate the expression of multi-
ple genes by interacting with the 3’UTR of target mRNAs to signal their degradation and/or
blocking their translation into proteins [2]. Furthermore, these molecules regulate genes in-
volved in a variety of cellular processes such as apoptosis, differentiation, proliferation, stress
response and metabolism, and their deregulation or dysfunction plays an important role in car-
cinogenesis and tumor progression [3–5]. Specific miRNA expression signatures have been
found in many malignancies, including colorectal cancer [6–8].
The miR-34 family is largely considered to be a tumor suppressor miRNA [9]. This family
consists of three members: miR-34a, generated from a transcriptional unit on the human chro-
mosome 1p36, and miR-34b and miR-34c, which are generated by processing of a bicistronic
transcript from chromosome 11q23. Both transcripts have been shown to be under the direct
positive control of p53 [10–12]. Several converging evidence demonstrated that ectopic expres-
sion of miR-34 family induces apoptosis, senescence, cell cycle arrest and inhibits migration
and invasion [9, 13]. Therefore, miR-34 family is thought to be important mediator of p53’s
tumor-suppressive activities. Besides, the miR-34a and miR-34b/c genes display varying levels
of DNA methylation in numerous types of tumors including colorectal cancer, and may there-
fore represent tumor suppressor genes [14–16]. Although previous reports have demonstrated
that down-regulation of miR-34 family members was associated with poor prognosis in several
types of malignancies [17–20], the prognostic value of miR-34 family in colon cancer has not
been systematically studied.
To evaluate the issue, we set out to systematically study the expression of the miR-34 family
in two large, independent cohorts of colon cancer patients. In addition, the association between
miR-34 expression and TP53 mutation, global gene expression was examined to clarify possible
mechanisms of miR-34 regulation. To our knowledge, this is the largest and systematic study
analyzing miR-34 expression in human colon cancer.
Material and Methods
Clinical samples
Pairs of primary colon tumor and adjacent non-tumor tissues came from 159 patients recruited
from the University of Maryland Medical Center or Baltimore Veterans Affairs Medical Center
between 1993 and 2002, and from 113 patients recruited from Queen Mary Hospital in Hong
Kong between 1991 and 2000. Detailed backgrounds for each tissue donor, including age, sex,
clinical staging, tumor location and survival times from diagnosis have been collected. The
final date of follow-up was December 31, 2008 for the American cohort and August 16, 2004,
for the Chinese cohort. Tumor histopathology was classified according to the World Health
Organization Classification of Tumor system.
Ethics Statement
This study was approved by the Institutional Review Board of the National Institutes of Health,
the Institutional Review Board of the University of Hong Kong/Hospital Authority Hong Kong
West Cluster, and the Institutional Review Board for Human Subject Research at the
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University of Maryland. All participants provided their written informed consent to participate
in this study, and the consent procedure was approved by the Institutional Review Board.
RNA isolation and quantitative reverse transcriptase-PCR
RNA from frozen tissue samples and cell lines was extracted using standard TRIZOL (Invitro-
gen, Carlsbad, California) methods. RNA was reverse-transcribed using TaqMan MicroRNA
Reverse Transcription Kit for miRNA assay (Applied Biosystems, Foster City, California).
Quantitative-PCR of microRNAs was performed using TaqMan assays (Applied Biosystems,
Foster City, California) according to the manufacturer’s instructions with the 7900 HT Real-
Time RT-PCR System (Applied Biosystems, Foster City). All assays were performed in tripli-
cate. All TaqMan probes were purchased from Applied Biosystems; hsa-miR-34a-5p (Assay
ID: 000426), hsa-miR-34b-5p (ID: 000427), hsa-miR-34c-5p (ID: 000428), RNU66 (ID:
001002). All microRNAs were normalized to RNU66 using the -ΔCt method. MicroRNA ex-
pressions were further normalized against the average expression of nontumor for each micro-
RNA for each cohort separately with the following equation, [-ΔCt(average nontumor)]–
[-ΔCt(sample)]. This sets the average nontumor expression = 1, with the log2 nontumor
expression = 0.
Affymetrix mRNA array and Ingenuity Pathway Analysis (IPA)
RNA from 56 tumors from the American cohort were analyzed on Affymetrix U133A mRNA
microarrays. Array data was imported and RMA normalized using Partek Genomic Suites 6.6.
Data is publically available at (GSE44861). The average expression of miR-34b and miR-34c
was used to analyze the association of miR-34b/c expression and global mRNA expression. In-
genuity Pathway Analysis (IPA 8.0, Redwood city, CA) was performed to identify molecules
and pathways potentially involved with the expression of miR-34 family.
Laser microdissection
For Laser microdissection (LMD), 5 pairs of frozen tumor and non-tumor tissues were ran-
domly obtained from the American cohort. Seven micron frozen sections for each tissues were
placed on the PEN membrane slides (Leica Microsystems). Sections were fixed in 75% ethanol
for 1 min, stained with Nuclear fast red for 2min, and dehydrated in a graded series of ethanol
and xylen. Slides were air-dried and then microdissected using the LMD6000 system (Leica
Microsystems). Microdissected epithelial and stromal cells from tumor and non-tumor tissues
were collected directly into Qiazol, and total RNA was isolated using the RNeasy Micro kit
(Qiagen) according to the manufacturer’s instructions. qRT-PCR was performed as
described earlier.
Statistical analysis
Relative expression quantitation of microRNA was calculated with RQ manager 1.2 (Applied
Biosystems). Expression values were used to analyze differences in microRNA expression be-
tween tumors and adjacent non-tumor tissues for all qRT-PCR data using Graphpad Prism
v5.0 (Graphpad Software Inc, San Diego, California). Wilcoxon matched-pairs tests were used
to compare microRNA expression between tumors and paired nontumor tissues. All trend
tests reported are Cuzick nonparamtric test for trend across ordered groups [21] and were per-
formed using Stata 9.2 (StataCorp LP, College Station, Texas). Kaplan-Meier analysis was per-
formed using Graphpad Prism v5.0. All p values were 2-sided and statistical significance was
set at p<0.05.
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Results
This study used two independent cohorts of colon cancer patients, one consisting of 159 cases
recruited from Maryland and the second cohort of 113 cases recruited from Hong Kong, China
(Table 1). The median follow-up times were 90.3 and 84.6 months for patients in the American
and the Chinese cohorts, respectively. The cohorts were similar in TNM staging, tumor histolo-
gy and cancer-specific mortality. The 5-year survival rate was 46.4% for the American cohort
and 49.6% for the Chinese cohort and were not significantly different from one another
(P = 0.36, Kaplan-Meier test). In addition to the racial, geographic and cultural differences be-
tween these 2 cohorts, the American cohort was considerably older (average 66.2 years vs 55.8
years) had a higher percentage of men (71% vs 50%). The Chinese cohort had a higher percent-
age of tumors located at distal colon (80% vs 20%). TP53 mutation evaluated by immunohis-
tochemistry was detected in 50.6% of the American cohort and 51.8% of the Chinese cohort.
Table 1. Characteristics of study populations and tumors.
American cohort Chinese cohort P-value
n = 159 n = 113
Area of recruitment Baltimore, MD Hong Kong, China
Age at enrollment (y)
Mean (SD) 66.2 (11.3) 55.8 (14.9) P<0.0001
Range 32–87 32–84
Gender, no. (%) P = 0.0003
Male 113 (71.1) 56 (49.6)
Female 46 (28.9) 57 (50.4)
Tumor locationa, no. (%) P = 0.0014
Distal 48 (58.5) 90 (79.6)
Proximal 34 (41.5) 23 (20.4)
Adenocarcinoma histology, no. (%) NS
Adenocarcinoma 142 (89.3) 105 (92.9)
Mucinous adenocarcinoma 16 (10.1) 7 (6.2)
Adenosquamous 1 (0.6) 0 (0)
Signet ring cell and mucinous 0 (0) 1 (0.8)
TP53 statusb, no. (%) NS
Wild-type TP53 39 (49.4) 52 (48.2)
Mutant TP53 40 (50.6) 56 (51.8)
TNM stagingc, no. (%) NS
I 21 (13.3) 9 (8.0)
II 54 (34.2) 37 (32.7)
III 65 (41.1) 48 (42.5)
IV 18 (11.4) 19 (16.8)
a Distal includes tumors located in or distal to the descending colon. Proximal tumors include tumors in or proximal to the splenic flexure. Tumor location
was available for all cases in the Chinese cohort and 82 cases in the American cohort.
b TP53 status was evaluated by immunohistochemistry of Formalin-Fixed Paraffin-Embedded (FFPE) tissues. Patients with available data were included.
c For one patient in the American cohort, it was unclear if that patient had stage III or stage IV colon cancer, therefore this patient was removed from
analyses stratifying by TNM stage.
doi:10.1371/journal.pone.0124899.t001
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MiR-34a, -34b and -34c are increased in colon cancer, and increased
miR-34b/c is associated with advanced tumors and poor prognosis
We performed TaqMan qRT-PCR of miR-34a, miR-34b and miR-34c in colon tumors and ad-
jacent non-tumor tissues from both the American and the Chinese cohorts. Unexpectedly, The
expression of these 3 miRNAs was significantly increased in tumors compared to non-tumor
tissues in both cohorts (Fig 1A and 1B). These increases were relatively small, but highly
Fig 1. ThemiR-34 family members significantly increase in colon tumors compared to adjacent non-
tumor tissues. (A, B) Dot plots represent miR-34a/b/c threshold cycle values from TaqMan qRT-PCR
normalized to U66 in American cohort (A) and Chinese cohort (B). Horizontal bars indicate median
expression value. Wilcoxon matched-pairs test was used. MiR-34a was not detectable in one patient and this
patient was excluded from all analyses.
doi:10.1371/journal.pone.0124899.g001
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significant. In the US cohort, the fold-change increase was 1.42, 1.27 and 1.25 for miR-34a,
-34b and -34c respectively. In the Chinese cohorts, the fold change increase was 2.26, 1.64 and
1.40, respectively. There was no significant association between miR-34a expression and TNM
staging (Fig 2A and 2B left panels), while increased miR-34b and -34c were associated with
higher TNM staging in both cohorts (test for trend, P<0.05; Fig 2A middle and right panels,
P<0.01; Fig 2B middle and right panels). MiR-34b and miR-34c are co-transcribed from a
bicistronic transcript and their expression should be highly correlated [9]. In agreement with
this, the expression of miR-34b and -34c were highly correlated in both tumors and non-tumor
tissues from each cohort (Pearson’s correlation r>0.9, P<0.0001; S1A and S1B Fig). Thus, we
used combined miR-34b/c expression into the following survival analysis. The American and
the Chinese cohorts were combined to increase the statistical power for this analysis and ex-
pression levels for each miRNA were dichotomized based on median values. There was no sig-
nificant association between miR-34a expression and prognosis (Fig 2C left panel). On the
Fig 2. The high expression of miR-34b/c is associated with advanced colon tumor and poor prognosis. (A, B) Tissues were ordered from TNM stage I
to IV tumors in the American cohort (A) and the Chinese cohort (B). Dot plots represent miR-34a/b/c threshold cycle values from TaqMan qRT-PCR
normalized to U66. Horizontal bars indicate median expression value. The Cuzick nonparametric test for trend was used to evaluate trends. (C) Kaplan-Meier
survival analysis of all stage cases in the American and Chinese combined cohorts stratified by median miR-34a expression and combined miR-34b/c
expression. *Cases with low miR-34b and/or low miR-34c. **Cases with both high miR-34b and high miR-34c.
doi:10.1371/journal.pone.0124899.g002
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other hand, colon cancer patients with high expression of both miR-34b and -34c in tumor
showed significant poor prognosis (log-rank P<0.05; Fig 2C right panel). When the survival
analysis was performed on each cohort separately, the differences were not statistically signifi-
cant (S2A and S2B Fig). In multivariate analysis, miR-34b/c was not significantly associated
with survival when adjusted for TNM staging (data not shown).
The association between miR-34 expression and TP53 mutation
Since miR-34a, miR-34b, and miR-34c were each systematically altered in colon tumors, we
next attempted to determine possible reasons for this altered expression. Several studies indi-
cate that p53 can bind to the promoter and activate the transcription of miR-34 family [10–
12]. To address this, we examined whether miR-34 expression was associated with TP53 muta-
tional status. TP53 mutational status can be examined either through immunohistochemistry
or through direct sequencing. In the present study, the TP53 mutational status was assumed to
be ‘wild-type’ or ‘mutant’ by immunohistochemical staining of p53 [22]. Contrary to our ex-
pectations, the expression of miR-34 family was not associated with TP53 mutational status in
either the American and Chinese cohorts (Fig 3A and 3B). Additionally, TP53 mRNA expres-
sion was not associated with miR-34a (R = 0.005, p = 0.97) or miR-34b/c (R = 0.013, p = 0.92)
expression based on microarray expression values of TP53 (S1 Table).
Ingenuity Pathway Analysis (IPA) predicts transcription regulators that
potentially associated with miR-34 up-regulation
In order to investigate potential reasons for the altered expression of the miR-34 family, we
used Affymetrix microarray data to identify genes that correlated with miR-34a and -34b/c and
examined these genes with Ingenuity Pathway Analysis (IPA). MiR-34b/c correlated with 649
genes in Affymetrix microarray data of 56 tumors from the American cohort (S1 Table;
P<0.001), and IPA was used to examine this set of genes. Increased expression of miR-34b/c
was associated with active transcriptional activity of TP53, SMAD3, CBL, SNAI1, HTT,
TWIST1 and CTNNB1 while it was associated with reduced transcriptional activity of MYCN,
AHR, SMAD7, MYC, SPDEF and PPARG (Table 2, S2 Table). Similar analysis on miR-34a ex-
pression identified 385 genes that were correlated with miR-34a (S1 Table; P<0.001). Increased
expression of miR-34a was associated with increased activity of 48 transcriptional regulators
including TP53 and decreased activity of 17 transcriptional regulators (S3 Table).
The comparison of miR-34 expression between colon epithelium and
stroma with laser microdissection (LMD) technique
Altered expression of oncogenic miRNAs in colorectal cancer stromal tissue might be associat-
ed with cancer progression [23]. To examine where the miR-34 family is expressed in, we ex-
tracted RNA from cancer epithelium, cancer stroma, normal adjacent epithelium and normal
adjacent stroma separately using laser microdissection for miR-34 expression analysis (S3 Fig).
Five colon tumor and 5 adjacent non-tumor frozen tissue samples were obtained form the
American cohort. MiR-34b and -34c expression levels in stroma were significantly higher as
compared with that of epithelium in both cancer tissues and in normal adjacent tissues (Fig 4
middle and right panels). MiR-34a showed similar trend although the differences were not sig-
nificant (Fig 4 left panel). We further examined the publicly available microarray dataset
(GSE35602), in which miRNA expression profiles of micro-dissected colon cancer stromal and
epithelial tissues were analyzed, demonstrating a clear trend of higher miR-34b and -34c ex-
pression in cancer stroma (S4 Fig). This microarray data are consistent with our own qRT-PCR
MiR-34 Family in Colon Cancer
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analysis using LMD samples, indicating that miR-34b and -34c are expressed at higher levels in
stomal tissues. In addition, we have performed H&E on 82 of the tissues from the American co-
hort to examine if there was an association with increased stromal area and any of the miR-34
family. There was no significant correlation between tumor/stroma ratio and expression levels
of miR-34 (S5 Fig). These findings based on LMD analyses suggest that stromal cells serve the
major source of miR-34b/c rather than epithelial cells. Hence, miR-34b/c expression detected
in macro-dissected tumor samples (as shown in Fig 1) seems to mainly represent stromal ex-
pression of miR-34b/c.
Discussion
In the present study, we demonstrated that: 1) miR-34a/b/c were increased in human colon
cancers compared to adjacent non-tumor tissues. 2) Increased expression of miR-34b/c was
Fig 3. TP53mutation is not associated with the expression of miR-34 family. (A, B) TP53 mutational
status was evaluated by immunohistochemistry using Formalin-Fixed Paraffin-Embedded (FFPE) tissues.
Dot plots represent miR-34a/b/c threshold cycle values of tumor tissue from TaqMan qRT-PCR normalized to
U66 in American cohort (A) and Chinese cohort (B). Horizontal bars indicate median expression value. Mann-
Whitney test was used. WT: wild-type p53, Mut: mutant p53.
doi:10.1371/journal.pone.0124899.g003
MiR-34 Family in Colon Cancer
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Table 2. List of Transcription Regulators that are potentially involved with miR-34b/c expression predicted by Ingenuity Pathway Analysis in 56
tumors.
Transcription Regulator Activation State z-score p-value of overlap Target moleculesa
TP53 Activated 3.618 7.50E-07 64 genes
SMAD3 Activated 3.289 4.48E-05 18 genes
CBL Activated 2.705 1.72E-03 5 genes
SNAI1 Activated 2.490 1.29E-04 7 genes
HTT Activated 2.400 3.63E-05 43 genes
TWIST1 Activated 2.256 7.71E-03 5 genes
CTNNB1 Activated 2.160 1.82E-05 36 genes
MYCN Inhibited -4.242 4.69E-08 26 genes
AHR Inhibited -4.118 4.11E-12 36 genes
SMAD7 Inhibited -3.698 3.43E-12 23 genes
MYC Inhibited -3.348 8.65E-05 43 genes
SPDEF Inhibited -3.290 1.05E-18 24 genes
PPARG Inhibited -2.210 4.23E-02 18 genes
a All target molecules are listed in S3 Table.
doi:10.1371/journal.pone.0124899.t002
Fig 4. miR-34 family tends to be expressed predominantly in stromal tissue. RNA samples from cancer epithelium, cancer stroma, normal adjacent
epithelium and normal adjacent stroma were extracted separately using laser microdissection technique from 5 paired samples in the American cohort. Dot
plots represent miR-34a/b/c threshold cycle values of tumor tissue from TaqMan qRT-PCR normalized to U48. Horizontal bars indicate median expression
value. Un-paired t test was used.
doi:10.1371/journal.pone.0124899.g004
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observed in more advanced tumors and associated with poor prognosis. 3) The expression of
miR-34 family was not associated with TP53 mutational status although pathway analysis
showed association between miR-34 expression and TP53 transcriptional activity. 4) The ex-
pression of miR-34b and -34c were increased significantly in stromal tissues compared
with epitheliums.
In colorectal cancer, prior studies have focused on a tumor suppressive function for miR-34
family as shown in many kinds of malignancy [9]. In vitro experiments have demonstrated
that ectopic expression of miR-34a into human colon cancer cell lines induced apoptosis, se-
nescence and inhibited migration and invasion by targeting E2F, SIRT1 and Fra-1 [24–26].
Considering the tumor suppressive function of miR-34 as shown previously, we had expected
that miR-34 family was suppressed in human colon cancer and decreased expression was asso-
ciated with poor prognosis when we started the present study. Previously, Roy et al. demon-
strated that the expression of miR-34a and miR-34c were down-regulated in colon cancer
specimens compared to adjacent colonic mucosa in small number expression analysis (n = 10)
[27]. Contrary to our expectation, all miR-34 family members were increased significantly in
colon cancer tissues compared with adjacent normal tissues, and increased miR-34b/c was as-
sociated with poor prognosis. As a matter of fact, the present data is consistent with several re-
cent reports analyzing miR-34 expression and its prognostic value. MiR-34 family members
have been found to increase in colorectal cancer [28], gastric cancer [29], renal cell carcinoma
[30, 31], lung squamous cell carcinoma [32] and pediatric leukemia [33]. In addition, Wang
et al. demonstrated that the miR-34a expression was higher in rectal cancer having more ad-
vanced TNM stage [28], and Svoboda et al. demonstrated that miR-34b up-regulation was as-
sociated with poor prognosis in triple-negative (ER-, PgR-, HER2-) breast cancer patients [34].
The fact that miR-34 family is up-regulated in human cancer and its up-regulation is associated
with poor prognosis, seems to be conflicted with tumor suppressive role of miR-34 demon-
strated in previous reports.
On the basis of these findings, we analyzed epithelial and stromal expression of miR-34 sep-
arately using laser microdissection technique to examine if cancer cells express miR-34. Inter-
estingly, all miR-34 family members, especially miR-34b and -34c, were increased in stromal
tissues compared with epithelium. In addition, the expression levels of miR-34 seemed to be
the highest in cancer stromal tissues. These findings suggest that colon cancer stroma is mainly
responsible for increased miR-34b/c expression, which were associated with advanced TNM
stage and poor prognosis. However, the reason for the up-regulation of miR-34 in stromal tis-
sue is still unclear. Nishida et al. demonstrated that several miRNAs were significantly altered
in cancer stroma, suggesting an important role of stromal miRNAs in cancer progression [23].
Stromal tissues consist of inflammatory cells, immunocompetent cells, endothelial cells and fi-
broblasts. One possible explanation of our findings is that miR-34 up-regulation in stromal tis-
sues might reflect inflammation of tumor tissues, as it is well known that inflammation
contributes to the development of cancer, including colon cancer [35]. Mathe et al. demon-
strated that mice treated with C. parvum, to induce inflammation, showed significant increase
of miR-21, miR-29b and miR-34a/b/c expression in the spleen [36]. Taken together, the fact
that miR-34b/c was increased in cancer stromal tissues, especially in more advanced colon can-
cer, might be associated with inflammation contributing to cancer progression. In a recent
study, Bu et al. have demonstrated that miR-34a regulated bimodal switch targets Notch in
colon cancer stem cells [37]. The finding may demonstrate one more possibility that different
level of miR-34 expression could be significant for miR-34-mediated interaction between
human colon cancer and stroma.
In the present study, we demonstrated conflicting findings. As shown in Fig 3, the expres-
sion of miR-34 family was not associated with TP53 mutational status. However, Ingenuity
MiR-34 Family in Colon Cancer
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Pathway Analysis demonstrated that Increased expression of miR-34a/b/c was associated with
active transcriptional activity of TP53 (Table 2, S2 Table, S3 Table).
Although it has been well known that miR-34 was direct target of p53, a recent study dem-
onstrated that mouse models that contain deletions for miR-34a, miR-34b and miR-34c still re-
tain p53 function and the expression of these microRNAs is largely independent of p53 status
[38]. In general, cancer stromal tissues are considered to harbor wild-type p53 regardless of
p53 mutational status of cancer tissues. Considering the fact that miR-34 was expressed in stro-
mal tissues predominantly, miR-34 detected in macro-dissected cancer tissues seems to be
mainly regulated by cancer stromal tissues harboring wild-type p53. That may be a plausible
explanation that the expression of miR-34 family was not associated with TP53 mutational sta-
tus of cancer.
Conclusions
In conclusion, we showed novel aspects of miR-34 family in human colon cancer. The demon-
strated findings imply that increased miR-34 in stromal tissues may have important roles in
colon cancer progression. Further analysis is needed to clarify the function and miR-34-medi-
ated interaction between human colon cancer and stroma.
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(TIFF)
S3 Fig. Laser microdissection technique. RNA samples from cancer epithelium, cancer stro-
ma, normal adjacent epithelium and normal adjacent stroma were extracted separately using
laser microdissection technique from 5 colon tumors and 5 adjacent non-tumor tissues ob-
tained from American cohort.
(TIFF)
S4 Fig. The miR-34 family members increase in stroma compared to epithelium. Dot plots
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